RxDoctor Payments Data

Rishi Bhardwaj, MD

Internal Medicine · Houston, TXNPI 1255514279

Payments from drug & device makers

$2,057in general payments, 2019–2025

Across 97 payments — averaging $21.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$304
  • Lilly USA, LLC$276
  • Novo Nordisk$222
  • AbbVie$220
  • Pfizer$152
  • GSK$141
  • plus $742 from 16 others

What the payments were for

  • Food & beverage$2,057100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,057 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$17,679
Medicare patients
72
Services billed
381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide25$28,702
JanuviaSitagliptin Phosphate19$27,517
FarxigaDapagliflozin Propanediol20$26,316
OzempicSemaglutide19$26,114
JardianceEmpagliflozin12$19,845
EliquisApixaban14$16,404
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$13,968
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$7,074
Nifedipine ErNifedipine63$1,827
Atorvastatin Calcium115$1,156
Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med17$1,053
Nano 2nd Gen Pen NeedlePen Needle, Diabetic12$909
Albuterol Sulfate HfaAlbuterol Sulfate39$733
SynthroidLevothyroxine Sodium11$683
Tamsulosin Hcl63$667

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$304$33,39131 claims
Lilly USA, LLCMounjaro$276$28,70225 claims
Novo NordiskOzempic$222$26,11419 claims
Boehringer IngelheimJardiance$71$19,84512 claims
PfizerEliquis$152$16,40414 claims
GSKTrelegy Ellipta$141$13,96814 claims
AbbVieSynthroid$220$68311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →